How plague-causing bacteria disarm host defense

May 24, 2007

Effector proteins are the bad guys that help bacterial pathogens do their job of infecting the host by crippling the body's immune system. In essence, they knock down the front door of resistance and disarm the cell's alarm system.

Now, researchers at the University of California, San Diego (UCSD) School of Medicine have identified a novel molecular target for an effector protein called YpkA, one of several effectors of the bacteria Yersinia – the pathogen responsible for the Middle Ages' "Black Death" and a virulent form of food poisoning today. Their study will be published online in the May 25 issue of Molecular Cell.

YpkA targets a host protein called Gaq, the messenger that transmits extracellular signals ("we are under attack!") into the host cell, so that it can mount a defense.

"The alarm signal sent by Gaq is intercepted by YpkA, which sets up a roadblock along several cellular pathways that Gq uses to deliver the alarm," said lead author Lorena Navarro, Ph.D., post-doctoral researcher in the lab of the study's principle investigator, Jack E. Dixon, Ph.D., professor of Pharmacology and Cellular and Molecular Medicine at the UCSD School of Medicine.

Identifying this new target is the first step to developing effective strategies for preventing disease, including means to fight antibiotic-resistant strains of Yersinia that could be used in biological warfare, according to Navarro.

The genus Yersinia includes three species of bacteria that are pathogenic to humans: Y. pestis is perhaps the most infamous, being responsible for the bubonic plague (also known as the Black Death), which killed more than 200 million people in the Middle Ages.

"This bacterial species could still be a threat today," said Navarro, adding that scientists had isolated an antibiotic-resistant strain of this species. In addition Y. pseudotuberculosis and Y. enterocolitica are big words for nasty, little bugs that cause what's commonly known as food poisoning. All three bacteria species find their way past the body's immune system through a sophisticated invasion system that injects the effector proteins directly into the host cell's cytoplasm.

"More than a decade after its discovery, our understanding of YpkA is still incomplete," Navarro said. "But Yersinia has maintained YpkA over millions of years, so it must be doing something important." The researchers speculate that YpkA plays an important role in disabling the body's immune system beyond its previously known role of disrupting the host cell's normal structure, which interferes with the cell's innate ability to engulf and destroy invading bacteria. "The question now becomes, why is Gaq targeted by YpkA?"

Source: University of California - San Diego

Related Stories

Recommended for you

Immune cells produce wound healing factor, could lead to new IBD treatment

September 20, 2017
Specific immune cells have the ability to produce a healing factor that can promote wound repair in the intestine, a finding that could lead to new, potential therapeutic treatments for inflammatory bowel disease (IBD), according ...

Researchers find way to convert bad body fat into good fat

September 19, 2017
There's good fat and bad fat in our bodies. The good fat helps burn calories, while the bad fat hoards calories, contributing to weight gain and obesity. Now, new research at Washington University School of Medicine in St. ...

New model may help science overcome the brain's fortress-like barrier

September 19, 2017
Scientists have helped provide a way to better understand how to enable drugs to enter the brain and how cancer cells make it past the blood brain barrier.

Cell-based therapy success could be boosted by new antioxidant

September 19, 2017
Cell therapies being developed to treat a range of conditions could be improved by a chemical compound that aids their survival, research suggests.

Study suggests epilepsy drug can be used to treat form of dwarfism

September 19, 2017
A drug used to treat conditions such as epilepsy has been shown in lab tests at The University of Manchester to significantly improve bone growth impaired by a form of dwarfism.

Research predicts how patients are likely to respond to DNA drugs

September 19, 2017
Research carried out by academics at Northumbria University, Newcastle could lead to improvements in treating patients with diseases caused by mutations in genes, such as cancer, cystic fibrosis and potentially up to 6,000 ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.